Government Consults May Be Pricey, But They Speed Review Times – Japan Officials
This article was originally published in PharmAsia News
Executive Summary
BOSTON - U.S. companies should take advantage of Japan's review consultation program to speed device approval and avoid unnecessary duplication of clinical trials, top Japanese device reviewers advise